Am J Obstet Gynecol

1. XU X, Long JB, Pollack CE, Desai VB, et al
   Peer Influence on Physicians in Adopting Opportunistic Salpingectomy at the Time of Hysterectomy.
   Am J Obstet Gynecol. 2025 Apr 18:S0002-9378(25)00229.
   

   >> Share

   
   

   
   BMC Cancer

2. TRAN NL, Wang Y, Quinn KM, Bilandzic M, et al
   Podocalyxin protects high grade serous ovarian cancer spheroids from NK cell infiltration and spheroid destruction.
   BMC Cancer. 2025;25:1674.
   

   >> Share

   
   

   
   Clin Cancer Res

3. VENEGAS L, Hodgson A, Oza AM
   Biomarkers in High-Grade Serous Ovarian Cancer: Context is everything.
   Clin Cancer Res. 2025 Oct 30. doi: 10.1158/1078-0432.CCR-25-2851.
   

   >> Share

   
   

   
   Curr Opin Obstet Gynecol

4. BESHAR I, Tostrud LJ, Ghezelayagh T, Blumenthal PD, et al
   Contraception in the setting of gynecologic and breast dysplasia.
   Curr Opin Obstet Gynecol. 2025;37:370-375.
   

   >> Share

   
   

   
   Gynecol Oncol

5. LINDGREN A, Benseler A, Hogen L, May T, et al
   Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.
   Gynecol Oncol. 2025;203:90-96.
   

   >> Share

   
   
6. WANG Y, Li J, Yang Y, Lu X, et al
   Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study.
   Gynecol Oncol. 2025;203:67-74.
   

   >> Share

   
   
7. ANDRES S, Tannous A, Kahn RM, Yeoshoua E, et al
   Survival outcomes in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer: Does the indication for neoadjuvant chemotherapy matter?
   Gynecol Oncol. 2025;203:35-42.
   

   >> Share

   
   
8. MANNING B, Banerjee S, Hawkins TB, Winn-Deen ES, et al
   Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples.
   Gynecol Oncol. 2025;203:26-34.
   

   >> Share

   
   

   
   J Clin Oncol

9. SHAH M, Fiero MH, Cheng J, Chen TY, et al
   Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
   J Clin Oncol. 2025 Oct 31:JCO2501933. doi: 10.1200/JCO-25-01933.
   

   >> Share

   
   
10. MONK BJ, Coleman RL, O'Malley DM, Moore KN, et al
    Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
    J Clin Oncol. 2025 Oct 31:JCO2501721. doi: 10.1200/JCO-25-01721.
    

    >> Share

    
    

    
    Oncology (Williston Park)

11. PROSPER AKANKWASA MBBS, Jackson Kakooza Mbbs, Aisha Abdullahi Ahmed Mbbs, Lewis CR, et al
    Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report.
    Oncology (Williston Park). 2025;39:410-413.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share